|Number of Estimates|
Market Cap: 190 Billion
Primary Exchange: NEW YORK STOCK EXCHANGE, INC.
Shares Outstanding: 1.77 Billion
Dividend: 4.75385938394855 (0.04%)
Industry: Pharmaceutical Preparation Manufacturing
Longest drawdown: 833 trading days
From: 2018-01-26 To: 2021-03-02
Akero Therapeutics Readies $75 Million IPO
via: SeekingAlpha at 2019-06-13 09:11:26:000
Quick Take Akero Therapeutics ( AKRO ) has filed to raise gross proceeds of $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing a treatment for metabolic diseases with high unmet clinical needs, with an initial focus on non-alcoholic steato… read more...
Prevail Therapeutics Proposes IPO Terms
via: SeekingAlpha at 2019-06-13 07:46:25:000
Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases… read more...
Bunker Dividend Growth Portfolio: Our 17th Dividend Aristocrat
via: SeekingAlpha at 2019-06-13 01:30:25:000
(Source: imgflip ) Note that to avoid reader confusion, I've shifted to a rotating portfolio update schedule. I'll now be providing just one update per week, alternating between my retirement portfolio (where I keep 100% of my life savings), and this model portfolio made up entirely of … read more...
June 2019 Stock Considerations
via: SeekingAlpha at 2019-06-12 23:24:27:000
After a wild May we seem to be trending back up in June. Of course, anyone in the DGI space already knows that these daily, weekly and monthly swings really don't matter to anyone with a very long-term time horizon. All we can do in the meantime is watch the market swing, stay in the game, fin… read more...
New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR
via: PR Newswire at 2019-06-12 14:00:00:000
NORTH CHICAGO, Ill. , June 12, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the Phase 3 clinical trials SELECT-EARLY and SELECT-COMPARE showing that patients receiving upadacitinib once-daily (15 mg or 30 mg,… read more...
AbbVie Inc. (ABBV) Management Presents at Goldman Sachs Global Healthcare Conference (Transcript)
via: SeekingAlpha at 2019-06-12 13:20:53:000
AbbVie Inc. (ABBV) Goldman Sachs Global Healthcare Conference June 12, 2019 11:00 AM ET Company Participants Mike Severino - Vice Chairman & President Rob Michael - Senior Vice President & CFO Conference Call Participants Terence C. Flynn - Goldman Sachs Presentati… read more...
Bert's May Dividend Income Summary
via: SeekingAlpha at 2019-06-12 05:44:02:000
Lanny said it best in his stock purchase article the month of May was actually wild! Every day presented a new twist, turn, and market swing. I would transfer cash to my brokerage and get ready to make a purchase. Then boom, the market would swing upward. Despite the madness, the div… read more...
Dividend Update - May 2019
via: SeekingAlpha at 2019-06-12 04:08:04:000
It has been a really busy year so far, and May was no different. You have probably noticed, I haven't been as active lately writing posts or buying stock. The main reason for this is because I just bought a house! So, I have basically just been saving all my capital to go toward that. Once thi… read more...
The Crazy Stuff That Happens To A Stock Portfolio
via: SeekingAlpha at 2019-06-12 01:09:46:000
It seems that every few months I get a portfolio shocker. There's often big news surrounding the individual stocks. I'll admit that I do not watch my holdings all that closely, but I certainly get all of the news feeds of my portfolio holdings courtesy of my Seeking Alpha home page. Yesterda… read more...
AbbVie's Skyrizi shows durable effect in late-stage psoriasis study; shares up 2%
via: SeekingAlpha at 2019-06-11 07:12:05:000
Two-year data from a Phase 3 clinical trial, IMMhance , evaluating AbbVie ( ABBV +2.3% ) and collaboration partner Boehringer Ingelheim's SKYRIZI (risankizumab) in adult patients with moderate-to-severe plaque psoriasis showed a sustained treatment benefit. The results are being presen… read more...
New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI(TM) (risankizumab) Maintains Complete Skin Clearance
via: PR Newswire at 2019-06-11 03:00:00:000
NORTH CHICAGO, Ill. , June 11, 2019 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results showing a significant number of patients treated with SKYRIZI (risankizumab) experienced complete skin clearance at week 94…. read more...
The Best Dividend Stocks To Buy During This Strong Market Rally
via: SeekingAlpha at 2019-06-11 01:13:43:000
(Source: imgflip ) Due to reader requests, I've decided to break up my weekly "Best Dividend Stocks To Buy This Week" series into two parts. One will be the weekly watch list article (with the best ideas for new money at any given time). The other will be a portfolio update. To also… read more...
How To Find Undervalued Stocks In The Healthcare Sector
via: SeekingAlpha at 2019-06-10 12:10:41:000
The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts … read more...
Dividend Stock Watch List - June 2019
via: SeekingAlpha at 2019-06-09 05:13:37:000
Hey, everyone. It's time once again to start thinking about where we are going to deploy some funds this month. As I mentioned in last month's dividend stock watch list, I'm going to focus on our four lowest sectors each month. This way, we stay nice and diversified and don't have a sector… read more...
Chewy IPO, Lululemon And Tesla On Tap (Stocks To Watch Podcast)
via: SeekingAlpha at 2019-06-09 03:30:00:000
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks.. If you are interested in listening to Stocks To Watch to start your Sunday (you can r… read more...
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|2019-10-14||2019-11-15||2019-10-15||2019-09-06||1.07||No Change QoQ|
|2019-07-12||2019-08-15||2019-07-15||2019-06-20||1.07||No Change QoQ|
|2019-04-12||2019-05-15||2019-04-15||2019-02-21||1.07||No Change QoQ|
|2018-10-12||2018-11-15||2018-10-15||2018-09-07||0.96||No Change QoQ|
|2018-07-12||2018-08-15||2018-07-13||2018-06-14||0.96||No Change QoQ|
|2017-10-12||2017-11-15||2017-10-13||2017-09-08||0.64||No Change QoQ|
|2017-07-12||2017-08-15||2017-07-14||2017-06-22||0.64||No Change QoQ|
|2017-04-11||2017-05-15||2017-04-13||2017-02-16||0.64||No Change QoQ|
|2016-10-12||2016-11-15||2016-10-14||2016-09-09||0.57||No Change QoQ|
|2016-07-13||2016-08-15||2016-07-15||2016-06-16||0.57||No Change QoQ|
|2016-04-13||2016-05-16||2016-04-15||2016-02-18||0.57||No Change QoQ|
|2015-10-13||2015-11-14||2015-10-15||2015-09-11||0.51||No Change QoQ|
|2015-07-13||2015-08-14||2015-07-15||2015-06-18||0.51||No Change QoQ|
|2014-10-13||2014-11-17||2014-10-15||2014-09-19||0.42||No Change QoQ|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|